These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 35730461)

  • 1. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
    Antonopoulos AS; Panagiotopoulos I; Kouroutzoglou A; Koutsis G; Toskas P; Lazaros G; Toutouzas K; Tousoulis D; Tsioufis K; Vlachopoulos C
    Eur J Heart Fail; 2022 Sep; 24(9):1677-1696. PubMed ID: 35730461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis.
    Donnellan E; Wazni OM; Saliba WI; Hanna M; Kanj M; Patel DR; Wilner B; Kochar A; Jaber WA
    Am J Cardiol; 2020 Aug; 128():140-146. PubMed ID: 32650908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis.
    Patel RK; Ioannou A; Razvi Y; Chacko L; Venneri L; Bandera F; Knight D; Kotecha T; Martinez-Naharro A; Masi A; Porcari A; Brown J; Patel K; Manisty C; Moon J; Rowczenio D; Gilbertson JA; Sinagra G; Lachmann H; Wechalekar A; Petrie A; Whelan C; Hawkins PN; Gillmore JD; Fontana M
    Eur J Heart Fail; 2022 Dec; 24(12):2355-2363. PubMed ID: 36575133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of potential transthyretin amyloid cardiomyopathy cases in the Brazilian public health system using a machine learning model.
    Zuppo Laper I; Camacho-Hubner C; Vansan Ferreira R; Leite Bertoli de Souza C; Simões MV; Fernandes F; de Barros Correia E; de Jesus Lopes de Abreu A; Silva Julian G
    PLoS One; 2024; 19(2):e0278738. PubMed ID: 38359001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; Davies DR; Scott CG; Fayyaz AU; Askew JW; McKie PM; Noseworthy PA; Johnson GB; Dunlay SM; Borlaug BA; Chareonthaitawee P; Roger VL; Dispenzieri A; Grogan M; Redfield MM
    JAMA Cardiol; 2021 Nov; 6(11):1267-1274. PubMed ID: 34431962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
    Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
    J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
    Madhani A; Sabogal N; Massillon D; Paul LD; Rodriguez C; Fine D; Helmke S; Winburn M; Kurian D; Raiszadeh F; Teruya S; Cohn E; Einstein AJ; Miller EJ; Connors LH; Maurer MS; Ruberg FL
    J Am Heart Assoc; 2023 Aug; 12(15):e028973. PubMed ID: 37486082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?
    Aus dem Siepen F; Hein S; Prestel S; Baumgärtner C; Schönland S; Hegenbart U; Röcken C; Katus HA; Kristen AV
    Clin Res Cardiol; 2019 Dec; 108(12):1324-1330. PubMed ID: 30953182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving epidemiology of transthyretin amyloid cardiomyopathy due to increased recognition in women.
    Prasad M; Kim M; Chandrashekar P; Zhao Y; Fischer KL; Nazer B; Masri A
    Int J Cardiol; 2023 Mar; 374():116-119. PubMed ID: 36587655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage.
    Law S; Petrie A; Chacko L; Cohen OC; Ravichandran S; Gilbertson JA; Rowczenio D; Wechalekar A; Martinez-Naharro A; Lachmann HJ; Whelan CJ; Hutt DF; Hawkins PN; Fontana M; Gillmore JD
    ESC Heart Fail; 2020 Dec; 7(6):3942-3949. PubMed ID: 32924285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary Transthyretin Amyloidosis Cardiomyopathy: The South Florida Experience.
    Trujillo L; Colombo R
    Am J Cardiol; 2022 Oct; 180():140-148. PubMed ID: 35945038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Counseling Family Members and Monitoring for Evidence of Disease in Asymptomatic Carriers of Amyloid Transthyretin Cardiac Amyloidosis.
    Barker N; Judge DP
    Am J Cardiol; 2022 Dec; 185 Suppl 1():S43-S50. PubMed ID: 36216601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis.
    Chacko L; Martone R; Bandera F; Lane T; Martinez-Naharro A; Boldrini M; Rezk T; Whelan C; Quarta C; Rowczenio D; Gilbertson JA; Wongwarawipat T; Lachmann H; Wechalekar A; Sachchithanantham S; Mahmood S; Marcucci R; Knight D; Hutt D; Moon J; Petrie A; Cappelli F; Guazzi M; Hawkins PN; Gillmore JD; Fontana M
    Eur Heart J; 2020 Apr; 41(14):1439-1447. PubMed ID: 31950987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
    Ruberg FL; Blaner WS; Chiuzan C; Connors LH; Einstein AJ; Fine D; Helmke S; Kurian D; Pandey S; Raiszadeh F; Rodriguez C; Sabogal N; Teruya S; Winburn M; Chung WK; Cohn E; Miller EJ; Kelly JW; Maurer MS
    J Am Heart Assoc; 2023 Apr; 12(8):e028534. PubMed ID: 37066788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States.
    Lau ATC; DiDomenico RJ; Kim K
    Int J Cardiol; 2024 Mar; 398():131598. PubMed ID: 37979789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
    Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
    Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex Differences in Transthyretin Cardiac Amyloidosis: Unraveling the Complexities in Epidemiology, Pathophysiology, Diagnosis, and Treatment.
    Vilches S; Martínez-Avial M; Méndez I; Gómez González C; Espinosa MÁ
    Curr Heart Fail Rep; 2024 Aug; 21(4):344-353. PubMed ID: 38775878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.